DK0686155T3 - Xanthinderivater som adenosin A1-receptor-antagonister - Google Patents
Xanthinderivater som adenosin A1-receptor-antagonisterInfo
- Publication number
- DK0686155T3 DK0686155T3 DK94910661T DK94910661T DK0686155T3 DK 0686155 T3 DK0686155 T3 DK 0686155T3 DK 94910661 T DK94910661 T DK 94910661T DK 94910661 T DK94910661 T DK 94910661T DK 0686155 T3 DK0686155 T3 DK 0686155T3
- Authority
- DK
- Denmark
- Prior art keywords
- adenosine
- pct
- receptor antagonists
- xanthine derivatives
- sec
- Prior art date
Links
- LRFVTYWOQMYALW-UHFFFAOYSA-N 9H-xanthine Chemical class O=C1NC(=O)NC2=C1NC=N2 LRFVTYWOQMYALW-UHFFFAOYSA-N 0.000 title abstract 2
- 229940124258 Adenosine A1 receptor antagonist Drugs 0.000 title 1
- 239000002598 adenosine A1 receptor antagonist Substances 0.000 title 1
- 229940083747 low-ceiling diuretics xanthine derivative Drugs 0.000 title 1
- 230000007278 cognition impairment Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
- A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
- C07D473/04—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms
- C07D473/06—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
- C07D473/04—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms
- C07D473/06—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3
- C07D473/08—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3 with methyl radicals in positions 1 and 3, e.g. theophylline
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US2350193A | 1993-02-26 | 1993-02-26 | |
| PCT/US1994/001009 WO1994019349A1 (en) | 1993-02-26 | 1994-01-27 | Xanthine derivatives as adenosine a1 receptor antagonists |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK0686155T3 true DK0686155T3 (da) | 1999-02-01 |
Family
ID=21815459
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK94910661T DK0686155T3 (da) | 1993-02-26 | 1994-01-27 | Xanthinderivater som adenosin A1-receptor-antagonister |
Country Status (19)
| Country | Link |
|---|---|
| US (1) | US5840729A (Direct) |
| EP (1) | EP0686155B1 (Direct) |
| JP (1) | JPH08512281A (Direct) |
| KR (1) | KR100315898B1 (Direct) |
| CN (1) | CN1041418C (Direct) |
| AT (1) | ATE169019T1 (Direct) |
| AU (1) | AU680241B2 (Direct) |
| CA (1) | CA2155130C (Direct) |
| DE (1) | DE69412073T2 (Direct) |
| DK (1) | DK0686155T3 (Direct) |
| ES (1) | ES2120025T3 (Direct) |
| HU (1) | HUT72677A (Direct) |
| IL (1) | IL108750A (Direct) |
| MX (1) | MX9401406A (Direct) |
| NO (1) | NO311920B1 (Direct) |
| NZ (1) | NZ262984A (Direct) |
| TW (1) | TW261532B (Direct) |
| WO (1) | WO1994019349A1 (Direct) |
| ZA (1) | ZA941176B (Direct) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1998041237A1 (en) * | 1997-03-18 | 1998-09-24 | Fujisawa Pharmaceutical Co., Ltd. | Preventives and remedies for hyperphosphatemia |
| IL139787A0 (en) | 1998-06-02 | 2002-02-10 | Osi Pharm Inc | PYRROLO [2, 3d] PYRIMIDINE COMPOSITIONS AND THEIR USE |
| US6680322B2 (en) | 1999-12-02 | 2004-01-20 | Osi Pharmaceuticals, Inc. | Compounds specific to adenosine A1 receptors and uses thereof |
| US6680324B2 (en) | 2000-12-01 | 2004-01-20 | Osi Pharmaceuticals, Inc. | Compounds specific to adenosine A1 receptors and uses thereof |
| US20020115635A1 (en) * | 2001-02-21 | 2002-08-22 | Pnina Fishman | Modulation of GSK-3beta activity and its different uses |
| DE60234118D1 (de) | 2001-11-30 | 2009-12-03 | Osi Pharm Inc | Verbindungen, die für Adenosin A1 und A3 Rezeptoren spezifisch sind, und deren Anwendungen |
| BR0215202A (pt) | 2001-12-20 | 2004-10-13 | Osi Pharm Inc | Compostos antagonistas seletivos a2b de pirimidina, sua sìntese e uso |
| AU2003239472A1 (en) * | 2002-05-15 | 2003-12-02 | Genzyme Corporation | Synthesis of benzonitriles and benzimidates |
| WO2004086047A2 (en) * | 2003-03-28 | 2004-10-07 | Bayer Healthcare Ag | Diagnostics and therapeutics for diseases associated with g-protein-coupled receptor adenosine a1 (adora1) |
| JPWO2005056016A1 (ja) * | 2003-12-09 | 2007-07-05 | 協和醗酵工業株式会社 | 高次脳機能障害の予防および／または治療剤 |
| US7592461B2 (en) | 2005-12-21 | 2009-09-22 | Bristol-Myers Squibb Company | Indane modulators of glucocorticoid receptor, AP-1, and/or NF-κB activity and use thereof |
| WO2007095161A2 (en) * | 2006-02-14 | 2007-08-23 | New York University | Methods and compositions for treating disorders associated with increased bone turnover and osteopenia |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE8817122U1 (de) * | 1988-12-22 | 1993-02-04 | Boehringer Ingelheim Kg, 55218 Ingelheim | Neue Xanthinderivate mit Adenosinantogenistischer Wirkung |
| US5047534A (en) * | 1990-03-26 | 1991-09-10 | Merrell Dow Pharmaceuticals Inc. | Selective adenosine receptor agents |
| DE4019892A1 (de) * | 1990-06-22 | 1992-01-02 | Boehringer Ingelheim Kg | Neue xanthinderivate |
| JPH0455150A (ja) * | 1990-06-22 | 1992-02-21 | Takata Kk | 助手席用エアバッグ装置 |
| US5087827A (en) * | 1991-02-11 | 1992-02-11 | Tektronix, Inc. | Variable voltage transition circuit |
| US5208240A (en) * | 1991-03-12 | 1993-05-04 | Merrell Dow Pharmaceuticals Inc. | 8-substituted purines as selective adenosine receptor agents |
| US5281607B1 (en) * | 1992-10-08 | 1998-05-19 | Univ New York | Method of using alpha 2-antagonists for the treatment of neurodegenerative diseases |
-
1994
- 1994-01-27 CN CN94191309A patent/CN1041418C/zh not_active Expired - Fee Related
- 1994-01-27 KR KR1019950703577A patent/KR100315898B1/ko not_active Expired - Fee Related
- 1994-01-27 AU AU62968/94A patent/AU680241B2/en not_active Ceased
- 1994-01-27 JP JP6518986A patent/JPH08512281A/ja active Pending
- 1994-01-27 HU HU9502495A patent/HUT72677A/hu unknown
- 1994-01-27 EP EP94910661A patent/EP0686155B1/en not_active Expired - Lifetime
- 1994-01-27 ES ES94910661T patent/ES2120025T3/es not_active Expired - Lifetime
- 1994-01-27 DE DE69412073T patent/DE69412073T2/de not_active Expired - Fee Related
- 1994-01-27 WO PCT/US1994/001009 patent/WO1994019349A1/en not_active Ceased
- 1994-01-27 AT AT94910661T patent/ATE169019T1/de not_active IP Right Cessation
- 1994-01-27 NZ NZ262984A patent/NZ262984A/en unknown
- 1994-01-27 DK DK94910661T patent/DK0686155T3/da active
- 1994-01-27 CA CA002155130A patent/CA2155130C/en not_active Expired - Fee Related
- 1994-01-27 US US08/500,991 patent/US5840729A/en not_active Expired - Fee Related
- 1994-02-21 ZA ZA941176A patent/ZA941176B/xx unknown
- 1994-02-22 TW TW083101485A patent/TW261532B/zh active
- 1994-02-23 IL IL10875094A patent/IL108750A/xx not_active IP Right Cessation
- 1994-02-24 MX MX9401406A patent/MX9401406A/es not_active IP Right Cessation
-
1995
- 1995-08-25 NO NO19953353A patent/NO311920B1/no not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| ZA941176B (en) | 1994-09-20 |
| US5840729A (en) | 1998-11-24 |
| HU9502495D0 (en) | 1995-10-30 |
| IL108750A (en) | 2000-09-28 |
| ES2120025T3 (es) | 1998-10-16 |
| DE69412073D1 (de) | 1998-09-03 |
| MX9401406A (es) | 1994-08-31 |
| HUT72677A (en) | 1996-05-28 |
| NO311920B1 (no) | 2002-02-18 |
| CN1118599A (zh) | 1996-03-13 |
| DE69412073T2 (de) | 1999-02-18 |
| CN1041418C (zh) | 1998-12-30 |
| JPH08512281A (ja) | 1996-12-24 |
| ATE169019T1 (de) | 1998-08-15 |
| NZ262984A (en) | 1997-05-26 |
| NO953353L (no) | 1995-08-25 |
| IL108750A0 (en) | 1994-05-30 |
| CA2155130A1 (en) | 1994-09-01 |
| EP0686155A1 (en) | 1995-12-13 |
| KR100315898B1 (ko) | 2002-02-28 |
| AU6296894A (en) | 1994-09-14 |
| WO1994019349A1 (en) | 1994-09-01 |
| CA2155130C (en) | 1994-09-01 |
| AU680241B2 (en) | 1997-07-24 |
| EP0686155B1 (en) | 1998-07-29 |
| NO953353D0 (no) | 1995-08-25 |
| TW261532B (Direct) | 1995-11-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE69622031D1 (de) | INDOLDERIVATE ALS cGMP-PDE INHIBITOREN | |
| DE69611377D1 (de) | 1,2,4-triazolo[1,5-c]pyrimidin-heterocyclische analoge mit antagonistischer aktivität auf dem adenosine a2a rezeptor | |
| ES2121193T3 (es) | Derivados de bencimidazoles. | |
| NO960630L (no) | Heterocykler anvendelige som neurokinin antagonister | |
| KR960700059A (ko) | 파킨슨씨 병 및 파킨슨 중후군의 치료에 카르바마제핀 및 옥스카르바제핀의 이용(application of carbamazepine and oxcarbazepine in the treatment of parkinson's disease and parkinsonian syndromes) | |
| ES2052717T3 (es) | Uso de derivados de indolona para la preparacion de medicamentos para el tratamiento de la enfermedad de parkinson. | |
| DE69327536D1 (de) | Fibrinogenrezeptor-antagonisten | |
| NO953353L (no) | Xantinderivater som adenosin-A -reseptorantagonister | |
| TR199900501T2 (xx) | Benzamin t�revleri ve bunlar�n ila� olarak kullan�m�. | |
| NO943133D0 (no) | Benzodiazepinderivater egnet til bruk som CCK-reseptorantagonister | |
| ES2098510T3 (es) | Antagonista de galanina. | |
| ATE113056T1 (de) | Künstliche rezeptor-analoge. | |
| ATE155683T1 (de) | Arzneimittel zur verhinderung der toleranzentwicklung während der behandlung mit benzodiazepin-rezeptor-bindenden wirkstoffen | |
| ATE153027T1 (de) | Zuckerderivate von makroliden | |
| SE9404438D0 (sv) | New process | |
| PT958290E (pt) | Derivados de 1,4-di-hidropiridina e seu uso em terapia | |
| ATE221068T1 (de) | Anellierte beta-carboline | |
| ITMI950956A0 (it) | Uso degli enantiomeri (s) di derivati 1,4-diidropiridinici per il trattamento dell'insufficienza cardiaca |